ArticleThe New England journal of medicine2008
Comprehensive treatment of extensively drug-resistant tuberculosis.
Article in The New England journal of medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 10 syntheses or guidelines pooled it, 400 citations in OpenAlex.
- Modeling treatment effect modification in multidrug-resistant tuberculosis in an individual patientdata meta-analysis.Statistical methods in medical research · 2022Pooled it
- The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis.BMC infectious diseases · 2016Pooled it
- Pooled it
- Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis.BMC infectious diseases · 2014Pooled it
- Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Pooled it
- WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.Antimicrobial agents and chemotherapy · 2013Pooled it
- Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2013Pooled it
- Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.PLoS medicine · 2012Pooled it
- Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2010Pooled it
- Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.PloS one · 2009Pooled it
- A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.The Lancet. Infectious diseases · 2026Trial
- A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease.The Journal of antimicrobial chemotherapy · 2024Trial
- Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.American journal of respiratory and critical care medicine · 2023Trial
- Combined computational and classical medicinal chemistry procedure to disclose novel pyrrole-based compounds as potential antituberculosis agents.Journal of computer-aided molecular design · 2026Article
- Reparations for Caribbean slavery and the potential impact on human well-being.BMJ global health · 2026Review
- Reimagining tuberculosis elimination in India: diagnostics, drug resistance, and digital health strategies.Frontiers in epidemiology · 2026Review
- Black Hairy Tongue as a Rare Adverse Effect of Linezolid in Multidrug-Resistant Tuberculosis: A Case Report.Clinical case reports · 2025Article
- Mycobacterium tuberculosis curli pili facilitates pathogenicity by modulating central carbon metabolism.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Article
- Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
27 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundExtensively drug-resistant tuberculosis has been reported in 45 countries, including countries with limited resources and a high burden of tuberculosis. We describe the management of extensively drug-resistant tuberculosis and treatment outcomes among patients who were referred for individualized outpatient therapy in Peru.
methodsA total of 810 patients were referred for free individualized therapy, including drug treatment, resective surgery, adverse-event management, and nutritional and psychosocial support. We tested isolates from 651 patients for extensively drug-resistant tuberculosis and developed regimens that included five or more drugs to which the infecting isolate was not resistant.
resultsOf the 651 patients tested, 48 (7.4%) had extensively drug-resistant tuberculosis; the remaining 603 patients had multidrug-resistant tuberculosis. The patients with extensively drug-resistant tuberculosis had undergone more treatment than the other patients (mean [+/-SD] number of regimens, 4.2+/-1.9 vs. 3.2+/-1.6; P<0.001) and had isolates that were resistant to more drugs (number of drugs, 8.4+/-1.1 vs. 5.3+/-1.5; P<0.001). None of the patients with extensively drug-resistant tuberculosis were coinfected with the human immunodeficiency virus (HIV). Patients with extensively drug-resistant tuberculosis received daily, supervised therapy with an average of 5.3+/-1.3 drugs, including cycloserine, an injectable drug, and a fluoroquinolone. Twenty-nine of these patients (60.4%) completed treatment or were cured, as compared with 400 patients (66.3%) with multidrug-resistant tuberculosis (P=0.36).
conclusionsExtensively drug-resistant tuberculosis can be cured in HIV-negative patients through outpatient treatment, even in those who have received multiple prior courses of therapy for tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.